FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and aims at treating cancer. There are used methods and a composition containing 1-[(4-chlorphenyl)methyl] -1H-indole-3-carboxalhyde and/or its analogues or derivatives.
EFFECT: group of invention enables higher clinical effectiveness in cancer ensured by inhibiting mutant RAS-protein activity.
24 cl, 6 tbl, 4 ex, 36 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CAFFEIC ACID BIOLOGICALLY AVAILABLE FOR ORAL USE, ASSOCIATED WITH ANTITUMOUR MEDICINAL AGENTS | 2007 |
|
RU2456265C2 |
| MACROCYCLIC COMPOUNDS, APPLIED AS HISTONE DEACETYLASE INHIBITORS | 2011 |
|
RU2565076C2 |
| LOW-MOLECULAR INHIBITORS OF N-TERMINUS ACTIVATION OF ANDROGEN RECEPTOR | 2009 |
|
RU2519948C2 |
| IDENTIFICATION OF LOW-MOLECULAR COMPOUNDS, RECOGNISABLE BY ANTIBODIES IN INDIVIDUALS WITH NEURODEGENERATIVE DISEASES | 2010 |
|
RU2566064C2 |
| N1-(4-(5-(CYCLOPROPYLMETHYL)-1-METHYL-1H-PYRAZOLE-4-YL)PYRIDINE-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF CK1 AND/OR IRAK1 FOR THE TREATMENT OF CANCER | 2018 |
|
RU2761457C2 |
| N- (PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2744358C2 |
| NEW SALICYLIC ACID DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALT, COMPOSITIONS AND METHOD FOR APPLICATION | 2013 |
|
RU2641903C2 |
| SPIRO OXINDOLE MDM2 ANTAGONISTS | 2010 |
|
RU2553269C2 |
| AMYLOID-BINDING AGENTS | 2010 |
|
RU2517174C2 |
| COMPOUNDS FOR CANCER TREATMENT | 2009 |
|
RU2514427C2 |
